2,493 Shares in Illumina, Inc. (NASDAQ:ILMN) Bought by HighPoint Advisor Group LLC

HighPoint Advisor Group LLC acquired a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 2,493 shares of the life sciences company’s stock, valued at approximately $334,000.

Other institutional investors also recently modified their holdings of the company. VisionPoint Advisory Group LLC grew its position in Illumina by 344.6% in the third quarter. VisionPoint Advisory Group LLC now owns 249 shares of the life sciences company’s stock valued at $34,000 after acquiring an additional 193 shares during the last quarter. Wetzel Investment Advisors Inc. bought a new position in Illumina in the 4th quarter valued at approximately $37,000. Gradient Investments LLC boosted its position in Illumina by 375.0% in the fourth quarter. Gradient Investments LLC now owns 285 shares of the life sciences company’s stock valued at $40,000 after buying an additional 225 shares in the last quarter. North Star Investment Management Corp. grew its stake in shares of Illumina by 183.0% during the fourth quarter. North Star Investment Management Corp. now owns 300 shares of the life sciences company’s stock worth $42,000 after buying an additional 194 shares during the last quarter. Finally, MeadowBrook Investment Advisors LLC acquired a new position in shares of Illumina during the fourth quarter worth $42,000. Institutional investors and hedge funds own 89.42% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the company. Barclays raised their price objective on Illumina from $85.00 to $100.00 and gave the company an “underweight” rating in a report on Wednesday, April 10th. Royal Bank of Canada reiterated an “outperform” rating and set a $253.00 target price on shares of Illumina in a research report on Tuesday, April 9th. OTR Global reaffirmed a “mixed” rating on shares of Illumina in a research note on Wednesday, March 20th. Jefferies Financial Group initiated coverage on Illumina in a research report on Monday, June 3rd. They set a “hold” rating and a $115.00 target price for the company. Finally, Robert W. Baird increased their price target on Illumina from $125.00 to $128.00 and gave the company a “neutral” rating in a research note on Friday, May 3rd. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat, Illumina has a consensus rating of “Hold” and an average target price of $158.14.

Illumina Trading Up 0.1 %

ILMN opened at $108.25 on Friday. The company has a market cap of $17.24 billion, a P/E ratio of -13.28 and a beta of 1.20. The company has a fifty day moving average price of $113.08 and a two-hundred day moving average price of $127.55. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.26. Illumina, Inc. has a 1-year low of $89.00 and a 1-year high of $202.85.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, May 2nd. The life sciences company reported $0.09 EPS for the quarter, beating analysts’ consensus estimates of $0.04 by $0.05. Illumina had a positive return on equity of 2.31% and a negative net margin of 28.71%. The business had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.05 billion. During the same period in the previous year, the company posted $0.08 EPS. The firm’s revenue was down 1.0% compared to the same quarter last year. Analysts predict that Illumina, Inc. will post 1.04 EPS for the current fiscal year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.